28407355|t|Extracellular vesicles from bone marrow derived mesenchymal stem cells protect against murine hepatic ischemia - reperfusion injury
28407355|a|Hepatic ischemia-reperfusion injury (IRI) and associated inflammation contributes to liver dysfunction and complications after liver surgery and transplantation. Mesenchymal stem cells (MSC) have been reported to reduce hepatic IRI because of their reparative immunomodulatory effects in injured tissues. Recent studies have highlighted beneficial effects of extracellular vesicles from MSCs (MSC - EV) on tissue injury. The effects of systemically administered mouse bone marrow derived MSC - EV were evaluated in an experimental murine model of hepatic IRI induced by cross clamping the hepatic artery and portal vein for 90 minutes followed by reperfusion for periods of upto 6 hours. Compared with controls, intravenous administration of MSC - EV 30 minutes prior to IRI dramatically reduced the extent of tissue necrosis, decreased caspase-3 positive and apoptotic cells, and reduced serum aminotransferase levels. MSC - EV increased hepatic mRNA expression of NACHT, LRR and PYD domains-containing protein 12 (Nlrp12), and the chemokine (C-X-C motif) ligand 1 (CXCL1), and reduced mRNA expression of several inflammatory cytokines such as IL-6 during IRI. MSC - EV increased cell viability and suppressed both oxidative injury and NF-κB activity in AML12 murine hepatocytes in vitro. In conclusion, the administration of EV derived from bone marrow derived MSCs may ameliorate hepatic IRI by reducing hepatic injury through modulation of the inflammatory response. This article is protected by copyright. All rights reserved.
28407355	0	22	Extracellular vesicles	T026	C3894683
28407355	28	39	bone marrow	T024	C0005953
28407355	48	70	mesenchymal stem cells	T025	C1257975
28407355	71	78	protect	T033	C1545588
28407355	87	93	murine	T015	C0026809
28407355	94	110	hepatic ischemia	T046	C0920569
28407355	94	131	hepatic ischemia - reperfusion injury	T037	C4303160
28407355	113	131	reperfusion injury	T037	C0035126
28407355	132	167	Hepatic ischemia-reperfusion injury	T037	C4303160
28407355	169	172	IRI	T037	C4303160
28407355	178	201	associated inflammation	T046	C0021368
28407355	217	234	liver dysfunction	T046	C0086565
28407355	239	252	complications	T046	C0009566
28407355	259	272	liver surgery	T061	C0193373
28407355	277	292	transplantation	T061	C0040732
28407355	294	316	Mesenchymal stem cells	T025	C1257975
28407355	318	321	MSC	T025	C1257975
28407355	345	351	reduce	T080	C0392756
28407355	352	363	hepatic IRI	T037	C4303160
28407355	381	391	reparative	T058	C1254363
28407355	392	408	immunomodulatory	T121,T129	C1527392
28407355	392	416	immunomodulatory effects	T080	C1280500
28407355	420	427	injured	T169	C0332664
28407355	428	435	tissues	T024	C0040300
28407355	469	487	beneficial effects	T080	C1280500
28407355	491	513	extracellular vesicles	T026	C3894683
28407355	519	523	MSCs	T025	C1257975
28407355	525	528	MSC	T025	C1257975
28407355	531	533	EV	T026	C3894683
28407355	538	551	tissue injury	T033	C2136639
28407355	568	593	systemically administered	UnknownType	C0678812
28407355	594	611	mouse bone marrow	T024	C1511243
28407355	620	623	MSC	T025	C1257975
28407355	626	628	EV	T026	C3894683
28407355	634	643	evaluated	T062	C0178628
28407355	650	675	experimental murine model	T008	C0887965
28407355	679	690	hepatic IRI	T037	C4303160
28407355	691	698	induced	T169	C0205263
28407355	702	716	cross clamping	T169	C1883710
28407355	721	735	hepatic artery	T023	C0019145
28407355	740	751	portal vein	T023	C0032718
28407355	759	766	minutes	T079	C0439232
28407355	779	790	reperfusion	T061	C0035124
28407355	795	802	periods	T079	C1948053
28407355	813	818	hours	T079	C0439227
28407355	834	870	controls, intravenous administration	T082	C0013125
28407355	874	877	MSC	T025	C1257975
28407355	880	882	EV	T026	C3894683
28407355	886	893	minutes	T079	C0439232
28407355	903	906	IRI	T037	C4303160
28407355	907	927	dramatically reduced	T080	C0392756
28407355	942	957	tissue necrosis	T042	C0027540
28407355	959	968	decreased	T081	C0205216
28407355	969	987	caspase-3 positive	T116,T126	C0291573
28407355	992	1007	apoptotic cells	T026	C3269134
28407355	1013	1020	reduced	T080	C0392756
28407355	1027	1043	aminotransferase	T116,T126	C0002594
28407355	1052	1055	MSC	T025	C1257975
28407355	1058	1060	EV	T026	C3894683
28407355	1061	1070	increased	T081	C0205217
28407355	1071	1078	hepatic	T029	C0205054
28407355	1079	1094	mRNA expression	T045	C1515670
28407355	1098	1146	NACHT, LRR and PYD domains-containing protein 12	T028	C1864814
28407355	1148	1154	Nlrp12	T028	C1864814
28407355	1165	1197	chemokine (C-X-C motif) ligand 1	T028	C0812445
28407355	1199	1204	CXCL1	T028	C0812445
28407355	1211	1218	reduced	T080	C0392756
28407355	1219	1234	mRNA expression	T045	C1515670
28407355	1246	1258	inflammatory	T169	C0333348
28407355	1259	1268	cytokines	T116,T129	C0079189
28407355	1277	1281	IL-6	T116,T129	C0021760
28407355	1289	1292	IRI	T037	C4303160
28407355	1294	1297	MSC	T025	C1257975
28407355	1300	1302	EV	T026	C3894683
28407355	1303	1312	increased	T081	C0205217
28407355	1313	1327	cell viability	T043	C0007620
28407355	1332	1342	suppressed	T169	C1260953
28407355	1348	1357	oxidative	T169	C0311404
28407355	1358	1364	injury	T080	C1510467
28407355	1369	1374	NF-κB	T116,T192	C0961340
28407355	1375	1383	activity	T052	C0441655
28407355	1387	1411	AML12 murine hepatocytes	T025	C0227525
28407355	1412	1420	in vitro	T080	C1533691
28407355	1441	1455	administration	T061	C1533734
28407355	1459	1461	EV	T026	C3894683
28407355	1475	1486	bone marrow	T024	C0005953
28407355	1495	1499	MSCs	T025	C1257975
28407355	1504	1514	ameliorate	T033	C0243095
28407355	1515	1526	hepatic IRI	T037	C4303160
28407355	1530	1538	reducing	T080	C0392756
28407355	1539	1553	hepatic injury	T037	C0160390
28407355	1562	1572	modulation	T082	C0443264
28407355	1580	1601	inflammatory response	T046	C1155266